Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
Silence Therapeutics PLC Sponsored ADR (SLN) Debt to Capital Ratio data is not available for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$0.16M |
|
$-20.96M |
|
$0.06M |
|
$0.10M |
|
$26.40M |
|
$-26.24M |
|
$5.29M |
|
$-20.96M |
|
$-20.96M |
|
$-20.96M |
|
$-20.96M |
|
$-20.96M |
|
$-20.96M |
|
$-26.24M |
|
$-26.09M |
|
47.23M |
|
47.23M |
|
$-0.45 |
|
$-0.45 |
|
| Balance Sheet Financials | |
$133.63M |
|
$1.66M |
|
$13.16M |
|
$146.79M |
|
$17.38M |
|
-- |
|
$55.35M |
|
$72.73M |
|
$74.06M |
|
$63.15M |
|
$74.06M |
|
47.23M |
|
| Cash Flow Statement Financials | |
$-44.98M |
|
$5.35M |
|
$0.01M |
|
$121.33M |
|
$82.03M |
|
$-39.30M |
|
$8.16M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.69 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
-- |
-- |
|
59.75% |
|
-16505.66% |
|
-16505.66% |
|
-- |
|
-13180.50% |
|
-13181.13% |
|
$-45.04M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.01 |
|
0.01M |
|
-28.30% |
|
-33.19% |
|
-14.28% |
|
-28.30% |
|
$1.57 |
|
$-0.95 |
|
$-0.95 |
|